AstraZeneca to build US.5 billion manufacturing plant in Singapore

AstraZeneca to build US$1.5 billion manufacturing plant in Singapore



ASTRAZENECA is planning to build a US$1.5 billion facility in Singapore to manufacture antibody drug conjugates (ADCs), or treatments that enable precision therapy for cancer.

Posted in

Riah Marton

I'm Riah Marton, a dynamic journalist for Forbes40under40. I specialize in profiling emerging leaders and innovators, bringing their stories to life with compelling storytelling and keen analysis. I am dedicated to spotlighting tomorrow's influential figures.

Leave a Comment